Thread by @DrEricDing

Vaccine trials for kids 5-11 expanded—possibly delayed. F.D.A. has asked the companies to include 3,000 children in the 5-to-11-year-old group, roughly double the original number of study participants. Unclear if EUA approval will be delayed or not. 🧵
nytimes.com/2021/07/26/us/…

2) Pfizer is on a faster timetable than Moderna, and may be able to meet F.D.A.’s expectations on a bigger trial size and still file a request to expand emergency authorization by the end of September. Reviewing all the safety and efficacy data will likely take FDA a few weeks.

3) Pfizer has previously said it expects to have results for the 5-to-11-year-old group in September, with results for children aged 2 to 5 shortly after that. A spokeswoman said Monday that the company had no updates on its timetable.

4) Many public health experts argue that, with so much attention focused on hospitalizations and deaths among older Americans infected with the coronavirus, the risk for children has been overlooked.

5) More than four million American children and adolescents have tested positive for the virus since the onset of the pandemic, the American Academy of Pediatrics reported last week. Of those, at least 346 have died.